17 Jul 2014 05:26
Final results from Immunodiagnostic Systems (IDS) were broadly in line with expectations, as the company outlined a new five-year strategy to double revenues by increasing the installed base of its IDS-iSYS instruments and its menu of tests. The AIM-listed company confirmed, as per its update in A
Read more